Neurocrine Biosciences Reports First Quarter 2022 Financial

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2022 and reiterated...

Related Keywords

Japan , United States , Japanese , Neurocrine Biosciences , Neurocrine Bioscience , Kevin Gorman , Neurocrine Biosciences Inc , Sosei Group Corporation , Linkedin , Mitsubishi Tanabe Pharma Corporation , Takeda Pharmaceutical Company , Nasdaq , Xenon Pharmaceuticals , Japanese Ministry Of Health , Idorsia Pharmaceuticals , First Quarter Net Product Sales , Product Sales Guidance Reiterated , Chief Executive Officer , Product Sales , Commercial Highlights , Japanese Ministry , Operating Expense Guidance , Future Milestones , Supplemental New Drug Application , Second Half , Online Data , Registrational Study , Line Registrational Data , Selectivet Type , Line Phase , Pediatric Epilepsy , Adrenal Hyperplasia , Major Depressive , Onset Seizure , Vesicular Monoamine Transporter , Calcium Channel , Epileptic Encephalopathy , Continuous Spike , Wave During Sleep , Corticotropin Releasing Factor Type , Isoxazole Propionic Acid , Orphang Protein Coupled Receptor , Sodium Channel , Bioscience Partners , East Asia , Takeda Pharmaceutical Company Limited , Webcast Today , Quarterly Report , Nc ,